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ABSTRACT 
This research paper intends to demonstrate that essential medicines on patent do pose a barrier to 
access in terms of affordability. The research undertaken provides some empirical evidence on 
the prices of essential medicines that are on patent. The focus of this is to show how patented 
medicines when sold in generic forms often prove to be much cheaper than the original form of 
medicines. The research, then, delves into the various agreements and laws such as the TRIPS 
agreement and the Industrial Property Act that provide for flexibilities such as compulsory 
licensing. The research then discusses how Kenya needs to make its IP rights regime more 
transparent and the need for putting up measures to prevent situations of evergreening. In 
conclusion IP rights do pose a barrier to access for essential medicines since branded medicines 
are much more expensive then generic medicines. 
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CHAPTER 1: INTRODUCTION 
Background of the problem 
Access to essential medicines in the developing countries is one of the most critical health issues 
faced. Many people living in developing countries face major challenges with regard to access to 
healthcare and essential medication. According to the World Health Organization "essential 
medicines" are defined as follows; "Essential medicines are those that satisfy the priority 
health care needs of the population. They are selected with due regard to public health 
relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential 
medicines are intended to be available within the context of functioning health systems at 
all times in adequate amounts, in the appropriate dosage forms, with assured quality and 
adequate information, and at a price the individual and the community can afford. The 
implementation of the concept of essential medicines is intended to be flexible and 
adaptable to many different situations; exactly which medicines are regarded as essential 
remains a national responsibility."1 
This paper intends to look at the effect that intellectual property rights (Patents) have on the 
prices of pharmaceutical medicines that are essential in Kenya, and it also intends to look at the 
effect of the TRIPS agreement (The Agreement on Trade-Related Aspects of Intellectual 
Property Rights). 
The TRIPS agreement makes an effort to create flexibilities through; compulsory licenses and 
government use order which helps in addressing issues of high price medicines, lack of supply 
and emergency public health situations. Other flexibilities include parallel importing, voluntary 
licenses, the Bolar exception and the research, experimental use exception, availability of new 
use pharmaceutical patents.2 
Fmthermore, the paper intends to look at the pricing of essential medicines that have been 
patented to see the effects of the patents on essential medicines. 
1 https://www.cugh.org/sites/defaultlfiles/1 06 WHO Essential Medicines List from Idea to I 
mplementation FINAL.pdf on 04/01/2017. 
2 Article 31, The Agreement on Trade-Related Aspects oflntellectual Property Rights, 1 January 
1995, 1869 UNTS 299. 
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Statement of the Probl em 
Intellectual Property rights related to medicines; Are Intellectual property rights an impediment 
for accessing essential medicines in Kenya. This paper focuses on whether Patents impede access 
to essential medicines. 
Hypothesis 
Kenya is facing an access to essential medicine problem as many lives are lost due to 
inaccessible medicines. Kenya is pati of the TRIPS agreement and other bilateral trade 
agreements with other countries which give patent protection to essential medicines hence 
triggering rise in prices of medicines. 
Resea rch questions 
~ What factors affect inaccessibility of essential medicines in Kenya? Are IP rights one of 
the factors? 
~ How multilateral trade agreements, bilateral trade agreements and domestic laws have 
affected the Intellectual Property Rights for access to essential medicines in Kenya. 
~ What is the way forward with regard to access to essential medicine in relation to 
Intellectual Property rights? 
Justification 
The question of access to medicine becomes a question of life and death in developing countries 
since many people in the developing countries to do not have access to medicine. One of the 
reasons is that the medicines are often very expensive, and few people can afford it. Many of the 
drugs being patented are by institutions such as universities, pharmaceutical companies. 
"Many of the world's most important medicines and public health devices are wholly or 
partly developed in academic laboratories. Their accessibility to those living in poor 
nations is profoundly affected by the research, licensing and patenting decisions made by 
universities... . As members of these institutions of higher learning, we believe that 
universities have an opportunity and a responsibility to improve global access to public 
health goods-particularly those they have helped develop." 3 
3 https://www.ncbi.nlm.nih.gov/pmc/miicles/PMC2636619/ on 02/0112017 
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One of the reasons that these prices are high is because of the incentives involved in research and 
development of these drugs; therefore this study seeks to show what has been implemented till 
date. 
Another factor that affects access to medicine in developing countries is Patents. Patents tend to 
create monopolies for the drug production; hence these become very expensive for the low 
income society to access. IP rights have been put in place with the intention of economic 
advancement which in tum helps contribute to the enrichment ofthe society i.e. through research 
and innovations. This, however, has been more favourable to the pharmaceutical companies 
rather than the public (especially in developing countries). 
Limitations 
The first limitation of this dissertation is the vast literature with regard to the topic at hand. This 
is because the dissertation will not cover all the relevant literature written on the topic. Many 
developing countries face similar problems hence there are many case studies one could refer to 
but this dissertation will only look at one case study; Kenya. 
The other major limiting factor would be time. This is because a lot of data can be collected 
however with the restraints of time the dissertation will not be able to look at all the essential 
medicines. 
Definition of terms 
MLEM: Model list of Essential medicines (20111 edition): According to the World Health 
Organisation they are "those that satisfy the priority health care needs of the population. 
They are selected with due regard to public health relevance, evidence on efficacy and 
safety, and comparative cost-effectiveness. Essential medicines are intended to be available 
within the context of functioning health systems at all times in adequate amounts, in the 
appropriate dosage forms, with assured quality and adequate information, and at a price 
the individual and the community can afford. 
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The implementation of the concept of essential medicines is intended to be flexible and 
adaptable to many different situations; exactly which medicines are regarded as essential 
remains a national responsibility." 4 
Agreement on trade related aspects of intellect ual property r ight s (TRIPS) 
The TRIPS agreement which is an agreement on trade related intellectual property rights, was 
formed in the year 1994 but came into force in 1995 under the precursor body of the General 
Agreement on Tariffs and Trade (GATT) and it currently consists of 162 members. Prior to the 
TRIPS Agreement, the Paris Convention was the first major treaty governing intellectual 
property rights. Under this agreement, many countries had excluded medicines from patentability 
and of those that did grant patentability, it was mainly for processes rather than product patents. 
Under Article 28 of the TRIPS agreement, patentability extends to both process and product 
patents. 
TRIPS was the only multilateral trade agreement that sought to protect the intellectual property 
rights worldwide. This was generally done by providing minimum standards for members to 
adhere to i.e. all member states to reform their national laws in order to comply with the TRIPS 
agreement. 
A11icle 7 of the TRIPS Agreement sets out the objectives of the agreement which states 
"The protection and enforcement of intellectual property rights should contribute to the 
promotion oftechnological innovation and to the transfer and dissemination of technology, to the 
mutual advantage of producers and users of technological knowledge and in a manner conducive 
to social and economic welfare, and to a balance of rights and obligations."5 
Article 8 of the Agreement provides for the public health interest and states as follows: 
"Members may, in formulating or amending their laws and regulations, adopt measures 
necessary to protect public health and nutrition, and to promote the public interest in sectors of 
vital importance to their socio-economic and technological development, provided that such 
measures are consistent with the provisions of this Agreement. "6 
From these two Articles it could be inferred that the TRIPS agreement has taken into account 
both the protection of intellectual property rights and the public health aspect. 
4https ://www.cugh.org/sites/default/files/106 WHO Essential Medicines List from Idea to I 
mplementation FINAL.pdf on 04/01/2017. 
5 Article 7, The Agreement on Trade-Related Aspects of Intellectual Property Rights 
6 Article 8, The Agreement on Trade-Related Aspects of Intellectual Property Rights 
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The TRIPS Agreement also includes some of the flexibilities in order to cater for the problem of 
access to medicines (including essential medicines). These flexibilities reduce the impact of 
patents i.e. they promote competition and therefore promote access to medicines. 
Article 30 of the agreement provides for exceptions for patent rights. They do not, however, give 
pmiicular exceptions to these patent rights. 
"Members may provide limited exceptions to the exclusive rights conferred by a patent, provided 
that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do 
not unreasonably prejudice the legitimate interests of the patent owner, taking into account of the 
legitimate interests of third parties."7 
Although here have been no set criteria of exceptions that every state must use; states have used 
the following as exceptions to rights related to patents; acts carried out for non-commercial 
purposes including experiments and scientific research that involve the invention; preparation of 
drugs by unit and on medical prescription in pharmacy dispensaries; tests carried out before the 
expiry of the patent to establish the bio-equivalence of generic drug; use of the invention by a 
third party that had used it bona fide before the date of application for the patent. 8 
When focusing on access to medicines, two exceptions are of impmiance, namely compulsory 
licensing and the Bolar exception, 
Bolar exception is used for the manufacturing generic products, it allows for manufacturers to 
prepare production procedures before the patent expires. This reduces the time spent after the 
patent has expired. 
Article 31 provides for Compulsory Licences and it states as follows : 
"Other Use Without Authorization of the Right Holder. .. Where the law of a Member allows for 
other use of the subject matter of a patent without the authorization of the right holder, including 
use by the government or third parties authorized by the government, the [twelve] provisions 
shall be respected. "9 
7 Article 7, The Agreement on Trade-Related Aspects of Intellectual Property Rights 
8 Opati L, Intellectual Property Rights in Kenya, Konrad Adenauer Stifung, Nairobi, 2009, 31 
9 Article 31, The Agreement on Trade-Related Aspects of Intellectual Property Rights 
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These are licenses that can be used as a tool in the context of access to medicines e.g. to reduce 
high prices of medicines, or when there are anti-competitive practices, or when patent holder 
doesn't supply the required medicines in the market to the population at large, in cases of public 
health emergency. 10 
Essentially these licences allow the government to interfere with the patent rights of the patent 
holder e.g. they can allow the manufacturing of generic medicines without the authorisation of 
the patent holder in the above mentioned circumstances. This can be done if certain conditions 
are met; they should reasonably compensate the patent holder and granting of a compulsory 
license should be for non-commercial purpose. 11 
Government Use Order relates to a situation where the government or its agent (a department, 
agency or person or a government ministry) exercises the right to exploit a patented invention 
without the authorization of the patent holder. 12 For government use, the prior consent of the 
patent holder or prior negotiations with the patent holder is not requirement but according to 
Article 31 adequate compensation must be paid. 13 
Intellectual Property rights 
These are rights that are used to protect the creations of the mind. Some of these include; 
inventions, music, literature. Intellectual rights provide with exclusive rights to the right holders, 
so as to restrict access and use their property from third parties. According World Intellectual 
Property Organisation (WIPO) Convention defines intellectual rights as including rights relating 
to: 
"Literary artistic and scientific works,· performances of performing artists, phonograms, and 
broadcasts; inventions in all fields of Iutman endeavor,· scientific discoveries; industrial 
designs,· trademarks, service marks, am/ commercial names and designations; protection 
against unfair competition; and all other rights resulting from intellectual activity in the 
industrial, scientific, literary or artistic fields." 14 
10 Opati, ' Intellectual Property Rights in Kenya', 24 
11 Opati, 'Intellectual Property Rights in Kenya' , 24 
12 Opati, ' Intellectual Property Rights in Kenya', 24 
13 Opati, 'Intellectual Property Rights in Kenya' , 24 
14 Article 2, Convention establishing the World Intellectual Property Organisation 
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This paper looks at how patents affect the public health sector in the context of access of 
essential medicines. 
Patents are mainly intellectual property rights that cover inventions. 15 According to TRIPS there 
is no specific definition of an invention. According to the Industrial Property Act; 
"invention" means a new and useful art (whether producing a physical effect or not), process, 
machine, manufacture or composition of matter which is not obvious, or any new and useful 
improvement thereof which is not obvious, capable of being used or applied in trade or industry 
and includes an alleged invention. 16 
The term of a patent, when granted from the filing date can extend up to 20 years. 17 
According to Article 27 of the TRIPS agreement, for a patent to be granted it must meet the 
"patentability criteria". It states as follows "patents shall be available for any inventions, 
whether products or processes, in all fields of technology, provided that they are new, involve 
an inventive step and are capable o(industrial application." 
It is important to note that the terms "inventive step" and "capable of industrial application" are 
synonymous to non-obvious and useful respectively. 18 
1. The invention must be "new", this entails that the invention must have been in the 
public domain or that the invention must not have been disclosed. If it is the case 
where the invention had already been in the public domain or knowledge, then the 
patent application would be rejected or that if the patent had already been granted 
it would be revoked as a consequence. Discoveries of natural minerals are also not 
regarded as inventions. In the year 1993, the University of Mississippi Medical 
Centre had been granted patent rights for "a new method of promoting healing of 
a wound by administering turmeric to a patient afflicted with a wound". It was 
later found that the use of turmeric had already been in use in India for centuries 
and thus the Council for Science and Technology of India successfully petitioned 
against the patent, contending that the invention was not new. 19 
15 Opati, 'Intellectual Property Rights in Kenya', 15 
16 Section 2, Industrial Property Act, 2001 
17 Article 33, Agreement on trade related aspects of intellectual property rights 
18 Article 27, Agreement on trade related aspects of intellectual property rights 
19 Opati, 'Intellectual Property Rights in Kenya', 16 
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2. The invention must involve "an inventive step", this entails that the invention 
must involve a development to prior art; it should include a "surprising effect" to 
the invention. It is also important that it should not be obvious to a person of 
ordinary skill in the field concerned. 20 
3. The invention must be "capable of industrial application", this essentially means 
that the invention should be useful in an industrial i.e. it should have an technical 
effect. Generally the WTO members differ as to what industrial application means 
e.g. under the US law the concept of 'utility' , so an invention can be granted 
patent rights for developments that are not necessarily industrial products but 
rather they are operable and capable of satisfying some function of benefit to 
humanity. 21 
The African Regional InteJlect ual Property Organizat ion (ARIPO) 
This paper also focuses on how ARIPO protocol on patents has affected access to medicines. 
This is because Kenya is a member to this organization and hence it is affected by some of the 
activities carried out within ARIPO. One such example is the ARIPO Protocol on patents and 
industrial designs (i.e. "Harare Protocol"). Currently there are 18 parties to this protocol namely: 
Botswana, The Gambia, Ghana, Kenya, Lesotho, Liberia, Malawi, Mozambique, Namibia, 
Rwanda, Sierra Leone, Sudan, Swaziland, United Republic of Tanzania, Uganda, Zambia, 
Zimbabwe and Democratic Republic of Sao Tome and Principe. 22 
The ARIPO Secretariat is in charge of receiving and processing patent, utility models and 
industrial design applications as well as to grant patents, utility models and industrial design on 
behalf of its Contracting Parties. When a patent application is received at the ARIPO office it 
undergoes the examination process, and upon examination the patent is either granted or 
rejected. In the circumstance that the application is deserving of a patent then the Office would 
20 Opati, ' Intellectual Property Rights in Kenya' , 16 
21 Opati, 'Intellectual Property Rights in Kenya', 17 
22 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
14. 
8 
notify the applicant and each designated state. 23 Rule 18( 4) of the Regulations to the Harare 
Protocol provides that the notification attaching the search and examination of the application 
shall be made public in each designated State. Once the notification has been received, the 
Contracting parties have six months to make a written communication to the ARIPO office 
objecting to the grant of the patent in its territory. The effect of such an objection by the 
Contracting State, would render the patent as ineffective in its territory. If the office does not 
receive an objection, consequently the ARIPO office "shall grant the patent, which shall have 
effect in those designated States which have not made the communication". 24 
Once granted, a patent is subject to provisions set out in the national patent law of each 
Contracting Party such as on compulsory licenses, forfeiture or use of the patented inventions in 
the public interest. 25 
This means that patents granted at ARIPO will have an impact in Kenya, hence it's important to 
take ARIPO granted patents into account since Kenya is a member of ARIPO. 
23 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
17. 
24 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
17. 
25 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 




Chapter 1: This chapter includes the background of the topic, the justification, the limitations 
and the relevant statutes and treaties that guide Intellectual Property rights within Kenya. 
Chapter 2: Theoretical framework. 
The main theories include Human rights and Human dignity, the Social contract theory (John 
Locke), Prospects theory and the theory on Reward on services rendered. 
Chapter 3: Case study 
This chapter explains the research questions in depth and also provides a case study on the Anti-
Counterfeit Act of2008; lastly it also provides the literature review for the dissertation. 
Chapter 4: Findings; 
This mainly project the statistics of the patented medicines in the Model list of Essential 
Medicines, the health statistics within the Kenyan population and give an overview of how the 
pharmaceutical situation is in Kenya. 
Chapter 5: Research questions: 
It answers the research questions as explained in chapter 3. 
This chapter also analyses different multilateral agreements such as TRIPS, ARIPO and it also 
looks at the Industrial Property Act of Kenya. Lastly it gives its conclusion and 
recommendations with regard to the topic. 
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CHAPTER 2: THEORETICAL FRAMEWORK 
The theories included in this chapter are; Human dignity and Human rights, the Social contract 
theory (John Locke), Prospects theory and the theory on Reward on services rendered. 
Human dignity and Human rights 
Access to essential medicine can be related to the right to health, which is a fundamental human 
right. There are other rights that are related to this right, and these include; the right to 
development, and the right to dignity. According to human rights, the right to health is 
connected to the principles of non-discrimination, equality, accountability, transparency and 
participation. 26 
Hence this study is based on the theoretical framework of human rights, which provides that 
access to medicine is crucial to the life of a human being. 
According to Article 1 of The Universal Declaration of Human Rights (UDHR) "All human 
beings are born free and equal in dignity and rights. They are endowed with reason and 
conscience and should act towards one another in a spirit of brotherhood. "27 This means that 
every human is equal and every human being has an intrinsic human dignity. The German 
philosopher Immanuel Kant held a view that all human beings have an intrinsic worth (dignity) 
and that all human beings are above from all creation. This is because human beings are rational 
beings i.e. they are free agents to make their own decisions, setting their own goals and guiding 
their conduct by reason. Thus it is imperative that all human beings must be respected for their 
intrinsic human dignity; hence the right to access medicine is one such right that is imperative for 
the dignity of every human being. This is because access to medicines for a human being helps in 
the flourishing of that person's life and therefore respecting the person 's human dignity. 
26 http://www.ohchr.org/EN/Issues/Development/Pages/ AccessToMedicines.aspx on 04/02/2017 . 
27 Article 1 Universal Declaration of Human Rights. 
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Article 27 of the UDHR states that "everyone has the right freely to participate in the cultural life 
of the community, to enjoy the arts and to share in scientific advancement and its benefits. 
Everyone has the right to the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he is the author."28 This means that the UDHR 
has provided for the protection of Intellectual property rights. Intellectual property rights are also 
imperative for the protection of property, a strike of balance between the protection of human 
dignity and the protection of property is crucial. This paper looks at the access to medicine issue 
which is related to the dignity of a human being and the effect of intellectual propetiy rights of 
those medicines. 
The Social Contract Theory (John Locke) 
This theory was articulated in the book Two Treatises in Government. In this theory John Locke 
believes that a man was born in the state of nature which entails a state of perfection whereby a 
man is free to make decisions without the interference of others. He stated that we all belonged 
equally to God and therefore we must never harm each other. Another aspect of his theory 
includes the protection of property; which is essential for the civil authority to protect which then 
brings about the idea of 'the social contract'. The executive arm of the government is responsible 
for every person's property and well-being. He also states in the effect that the property owned 
by people should be limited; so that one should not take more than what one needs or can use.29 
This is related to the topic because it is the State's duty to protect the interests of its citizens, 
whether they are the property owners (Patent owners) or whether they are the public (who need 
access to essential medicine). It is, therefore, the State's responsibility to strike a balance 
between these two groups of people, especially with regard to access of essential medicines. This 
could be done by State interference (through laws) that allow for access to such medicines. 
John Locke believed that property rights were linked to labour of a person. This means if a 
person had expended his or her labour on the property, then the property belonged to that 
person.30 
28 Article 27, Universal Declaration of Human Rights 
29 http://www.iep.utm.edu/soc-cont/ on 30/08/2017 
30 Ndlovu L, ' Access to medicines under the world trade organisation TRIPS agreement: A 
comparative study of select SADC countries', Thesis for doctor of laws, University of South 
Africa, May 2014, 32. 
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This applies to intellectual property rights because intellectual property is seen as labour 
expended hence the Patent owners of the essential medicines have a right to the medicines. This, 
however, does not entail that the State has no responsibility towards the protection of its citizens 
from the lethal diseases. Hence it is an obligation upon the State to balance the rights of these 
patent owners of the 
Criticism of this theory is that Property rights are seen as the only reward mechanism available 
for the labourer (Patent owner). This, however, is not always the case because other reward 
mechanisms include awards, fees, gratitude, acknowledgment, praise, security, power, status, and 
public financial support. 31 Also if efforts of the labourer are disproportionate to the property 
rights granted, then granting of such rights would be ineffective. When looking at efforts 3 points 
are taken into consideration. These include; (I) how hard someone tries to achieve a result, (2) 
the amount of risk voluntarily incurred in seeking this result, and (3) the degree to which moral 
considerations played a role in choosing the result intended. The harder one tries, the more one is 
willing to sacrifice, and the worthier the goal, the greater the property rights. 32 
Prospects Theory 
According to this theory Patents provide an incentive for the inventor. It provides with legal 
security to promote venture capital, search for market opportunities, make investments and 
promote research and development. This theory justifies that patent owners of medicines should 
be given exclusive rights to their inventions so as to promote investments and research The 
criticism of this theory is that it bars competition because it does not allow for researchers to 
work on the same research. For example the Wright brothers who were the inventors of the 
modem airplane used their patent to impede the efforts of other inventors such as Curtis. A 
representative of Curtis had to remark that, 'a man has to have ten years in law school before he 
has had a chance of becoming an aviator'. 33 
31 Hettinger E, ' Justifying Intellectual Property' Volume 18 Philosophy and Public Affairs 
(1989), at 41 
32 Hettinger E, ' Justifying Intellectual Property' 42 
33 Ndlovu L, ' Access to medicines under the world trade organisation TRIPS agreement: A 
comparative study of select SADC countries', Thesis for doctor of laws, University of South 
Africa, May 2014, 36. 
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Theory on reward for services rendered 
This theory was largely propounded by Adam Smith. In his view, inventors must be rewarded for 
their inventions by the society because they have contributed to the society. Hence recognition 
and the protection of IP rights is necessary for the inventor and this has to be granted by the 
society. One of the criticisms of this theory is that whether the inventor should be rewarded for 
his effort or for the usefulness of their invention to the society, and what happens in the case of 
accidental inventions- how is the inventor supposed to be rewarded?34 
34 Ndlovu L, ' Access to medicines under the world trade organisation TRIPS agreement: A 
comparative study of select SADC countries ', Thesis for doctor of laws, University of South 
Africa, May 2014, 35. 
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CHAPTER3 
This Chapter expounds on the research questions posed in Chapter 1, it also provides a case 
study of The Anti -Counterfeit Act of 2008 and whether it was constitutional. Finally, the chapter 
provides a literature review of the dissertation. 
RESEARCH QUESTIONS 
As for the first research question; what factors affect inaccessibility of essential medicines in 
Kenya? Are IP rights one of them? This question generally looks into the different factors that 
have an effect on the accessibility of essential medicines to the general the public. Accessibility 
in this context refers to the price ranges of the various essential medicines. It also entails 
availability and affordability of safe medicines at the public and private health care facilities 
throughout the country. One of the main issues that hinder such accessibility of essential 
medicines is the deep poverty levels within the country. The aim of this question is to compare 
whether patents of essential medicines are affecting the price ranges of these medicines hence 
affecting accessibility of these medicines to the wider public. 
As for the second question; how multilateral trade agreements, bilateral trade agreements and 
domestic laws have affected the IP rights for drugs in Kenya as at 2017. This research question 
explores into the TRIPS agreement (Agreement on trade related aspects of intellectual property 
rights); which is a multilateral trade agreement that Kenya is a party to . Hence it will delve into 
the different principles espoused in the TRIPS agreement. It will also delve into provisions 
related to patents such as the safeguard mechanisms in practice from the TRIPS and Doha 
Declaration and public health. Lastly this research question shall also probe into the domestic 
laws of Kenya such as the Industrial Property Act of Kenya 2001 which include some of the 
mechanisms in the TRIPS agreement. It will further expound on some of these mechanisms such as 
licensing mechanisms and parallel importation with regard to Kenya. 
The last research question on what is the way forward with regards to the easy access to medicine 
in relation to the Intellectual Property rights; this will be tackled in the last chapter of the 
dissertation. It involves recommendations and the conclusion of the dissertation. 
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CASE STUDY; Patricia Ase r o Ochieng and 2 others vs. Attorney General and 
Another (Petition No. 409 of 2009 in the High Court of Kenya) - The case on the Anti-
Counterfeit Act of 2008. 
In this case three petitioners, who were living with HIV, petitioned the court that section 2 of the 
Anti- Counterfeit Act of 2008, which defines counterfeiting, was confusing the term counterfeit 
medicine with generic medicine. The petitioners who were living with HIV were heavily relying 
on generic medicines, and this Act sought to criminalise the manufacture, sale and distribution of 
generic medicines in Kenya. Hence, it posed as a barrier to the accessibility of affordable generic 
medicines in the country.35 They argued that this Act was in contravention to Article 43 of the 
2010 Constitution of Kenya which states that "every person has the right to the highest attainable 
standard of health, which includes the right to health care services, including reproductive health 
care."36 
Section 2 of The Anti-Counterfeit Act of 2008 defined counterfeiting as "according to the Act, 
means taking the following actions without the authority of the owner of intellectual 
property right subsisting in Kenya in respect of protected goods-
(a) the manufacture, production, packaging, re-packaging, labelling or making, whether in 
Kenya, of any goods whereby those protected goods are imitated in such manner and to 
such a degree that those other goods are identical or substantially similar copies of the 
protected goods; 
(b) the manufacture, production or making, whether in Kenya, the subject matter of that 
intellectual property, or a colourable imitation thereof so that the other goods are 
calculated to be confused with or to be taken as being the protected goods of the said owner 
or any goods manufactured, produced or made under his license; 
(c) the manufacturing, producing or making of copies, in Kenya, in violation of an author's 
rights or related rights;"37 
35 Patricia Asero Ochieng and 2 others v Attorney General and Another [2009] 
36 Article 43, Constitution of Kenya (20 1 0) 
37 Section 2, The Anti-Counterfeit Act (Act No. 13 of2008) 
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For the purposes of this case study, generic medicines are those medicines that are similar to the 
original medicine. They are those medicines that are genuine because they contain the requisite 
active ingredients hence are of good quality. They may only differ in appearance or flavour. 38 
Generic drugs are less expensive than the original drugs because the manufacturers did not have 
to incur the cost related to research (which was already incurred by the original manufacturer). 
Generic goods in Kenya have had a positive impact with regard to access; HIV, Malaria and TB 
treatment prices have reduced by 80% since 2001.39 
The broad definition used for counterfeiting proves to be very problematic for the production of 
generic goods. According to Article 51 of the TRIPS agreement counterfeiting relates to 
counterfeit trade mark goods and pirated copy right goods and not generic medicines. Counterfeit 
trademark goods refer to goods, "including packaging, bearing without authorization a 
trademark which is identical to the trademark validly registered [in Kenya] in respect of 
such goods, or which cannot be distinguished in its essential aspects from such a 
trademark, and which thereby infringes the rights of the owner of the trademark in 
Kenya;".40 While Pirated copyright goods refer to goods "which are copies made without the 
consent of the right holder or persons duly authorized by the right holder in Kenya and 
which are made directly or indirectly from an article where the making of that copy would 
have constituted an infringement of a copyright or a related right in Kenya."41 
38http://kelinkenya.org/wp-content/uploads/20 10/1 0/ Anti -Counterfeit-Act -to-Access-Generic-
Medicines-in-Kenya-booklet. pdf on 19/09/2017 
39http ://kelinkenya.org/wp-content/uploads/20 1 011 0/ Anti -Counterfeit -Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
40http ://kelinkenya.org/wp-content/uploads/20 1 0/1 0/ Anti -Counterfeit-Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
41 http://kelinkenya.org/wp-content/uploads/20 10/1 0/ Anti -Counterfeit-Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
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The second issue of the Anti- Counterfeit Act was the criminalization of manufacturing, 
production and packaging of similar goods. Section 32 of the Act provides for the offences of 
counterfeiting, whereas under the TRIPS agreement there is no obligation upon Kenya to 
criminalize such disputes because these disputes are of a civil nature and not a criminal nature. 42 
The third contention of the Act is that under Section 25 inspectors of the Board (provided under 
the Act), are given excessive powers to seize suspected counterfeit goods. This poses as a threat 
to generic medicines since they could be regarded as counterfeit products hence impeding access 
to such medicines. Also these inspectors do not have the requisite expertise to determine the 
quality of the generic medicines (whereas quality is a key factor in determination of counterfeit 
medicines). 43 
Fourthly, the Act does not give a specified period oftime within which the seized goods are to be 
held. Hence, the expiry of the seized goods (medicines) could amount to a major problem and 
thus creating a hindrance for the access to medicine and a timely treatment.44 
Lastly, the Act in Section 34 allows for the government to detain goods that are to be transported 
to other countries. This poses as a challenge because now many other countries will be affected 
by the government interference on generic medicines, therefore, threatening access to 
medicines.45 
The above mentioned challenges of Anti Counterfeit Act could have serious consequences for 
accessing affordable medicines (including essential medicines) throughout the region. The High 
Court ruled for the petitioners and declared Sections 2, 32 and 34 of the Act as unconstitutional. 
It was to this effect that Judge Mumbi Ngugi stated that "the Act is vague and could undermine 
access to affordable generic medicines since it failed to clearly distinguish between counterfeit 
and generic medicines." 
42http://kelinkenya.org/wp-content/uploads/20 10/10/ Anti -Counterfeit-Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
43http :/ /kelinkenya.org/wp-content/uploads/20 1 0/1 0/ Anti -Counterfeit-Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
44http:/ /kelinkenya.org/wp-content/uploads/20 1 0/1 01 Anti -Counterfeit-Act -to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
45http :/ /kelinkenya.org/wp-content/uploads/20 1 0/1 0/ Anti -Counterfeit-Act-to-Access-Generic-
Medicines-in-Kenya-booklet.pdf on 19/09/2017 
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LITERATURE REVIEW 
With regard to literature on IP rights and access to medicine in Kenya, Dr Ben Sihanya, Prof 
Moni Wekesa and Linda Opati have published a book namely "Intellectual Property Rights in 
Kenya". She has dedicated a chapter in the book on how IP rights have affected the access to 
medicines in developing countries; it expounds on the TRIPS agreement and how it has been 
implemented and whether Kenya has been flexible in the implementing access to medicines. 
At first it looks at the definition of patents and the justifications for it in the pharmaceutical 
company. This includes the furthering of economic objectives and enrichment to society, by 
promoting the domestic industries and international trade.46 
It then looks at the issue of research and development as a justification and whether it is a valid 
justification since the costs for research and development are quite low compared to how much 
the pharmaceuticals earn due to the patents.47 
The chapter takes a look into the international community pre-TRIPS; and observes that there 
was non-uniformity in the granting of patents; this means that there were few countries that 
granted pharmaceuticals patents whilst other countries refused to grant patents to pharmaceutical 
companies. The chapter then delves at the post-TRIPS period whereby The World Trade 
Organization (WTO) was given the responsibility to be a multilateral governing body dealing 
with the rules of trade between countries with regards to pharmaceutical patents.48 
It also comments on the Doha declaration as a means to explain the flexibilities mentioned in the 
TRIPS agreement about public health; compulsory licenses, parallel importation and exhaustion 
of IP rights, voluntary licensing, availability of new use pharmaceutical patents, government use 
licenses, research exemption, early working (bolar exception) and test data protection.49 
As for compulsory licenses, the TRIPS agreement allows for countries to manufacture generic 
goods without the consent of the patent holder but with certain conditions such as failed 
negotiations with patent holder and adequate remuneration. so The Doha Declaration mentions 
that the countries can choose the grounds upon which compulsory licenses are granted. 
46 Opati, 'Intellectual Property Rights in Kenya', 19. 
47 Opati, 'Intellectual Property Rights in Kenya', 19. 
48 Opati, 'Intellectual Property Rights in Kenya' , 19. 
49 Opati, 'Intellectual Property Rights in Kenya', 24. 
so Opati, 'Intellectual Property Rights in Kenya', 24. 
19 
Parallel importation and exhaustion of IP rights involve a patent holder losing his/her rights due 
to the release of the product (through importation) into the commercial market, by another 
generic company. 51 The Doha Declaration states in the effect that the country should provide for 
specific legislation for this to occur. Voluntary licenses mean the patent holder can choose to 
give licenses to another company to use its patented rights in return for a royalty fee . 52 
Availability of new use pharmaceutical patents or ever greening refers to the patentability of new 
uses of the product after the patent has expired. 53 TRIPS has provided that patents only be 
granted to products or processes which are new, involve an inventive step and are industrially 
applicable. Hence countries should refrain from granting patents on the basis of new uses in 
relation to medicines. Bolar exceptions are when generic manufacturers are allowed to prepare 
production and regulatory procedures before the expiration of patents. 54 
The chapter also looks into the implementation of TRIPS in Kenya as at 2009; For instance the 
Industrial Property Act of 2001 which includes TRIPS compatible mechanisms for access to 
medicines such as exhaustion of intellectual property rights. 
51 Opati, 'Intellectual Property Rights in Kenya', 28 . 
52 Opati, 'Intellectual Property Rights in Kenya', 29. 
53 Opati, 'Intellectual Property Rights in Kenya' , 32. 
54 Opati, 'Intellectual Property Rights in Kenya', 19. 
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CHAPTER 4: FINDINGS 
Methodology 
This chapter mainly includes empirical data that sought to compare price differences between 
generic essential medicines on patent and original essential medicines on patent. 
Due to constraints of time, the data gathered is not exhaustive thus these findings a1m at 
providing the broad underlying spectrum of prices of some essential medicines. The medicines 
chosen are from the MLEM 20111 edition and they are assumed to be on patent according to a 
WIPO Research carried out by Reed F Beall form the University of Ottawa. 
Interviews were also conducted with pharmacists, scholars of access to medicine within the 
Kenyan region, and some of data gathered was from key organisations (such as the World Health 
Organisation, ARIPO and research papers) that provide impmiant data relating to the subject. 
Kenya's Pharmaceutical Statistics as per th e Pharmaceutical Policy in the East 
African Community55 
Kenya is the largest and most developed pharmaceutical manufacturing sector in EAC region. 
Its branded and generic market share is 44% and 56%, respectively. The market share of locally 
produced pharmaceuticals is currently at 28%, of which 35-45% of the locally produced 
medicines are exported to neighbouring countries. There is a 15% marginal preference scheme 
for local products by government tenders. The local production meets 30% of the national 
demand of pharmaceuticals. There is generally a negative market perception of local 
manufacturers. The local production is predominantly generic and raw materials mostly imported 
55 Mashingia J,' Pharmaceutical Policy m the East African Community: Burundi, Kenya, 
Uganda, Rwanda, Tanzania', 18. 
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World Health Organization Statistics: 
------------- ------------·-------------------------------








WHO TOP TEN CAUSES OF 
DEATH AS AT 2012 
Top 20 Patent Pharmaceutical Applicants in ARIPO Between 1/1/2003 and 31/12/2013 
1. Boehringer Ingelhiem International 11. Iceutica Pty. Ltd 
GMBH 
2. Pftzer Inc. 12. Pfizer Limited 
3. Pfizer Products INC. 13. Warner-Lambert Company LLC 
4. Les Laboratoires Servier 14. Bayer Intellectual Property GMBH 
5. Gilead Sciences INC 15. Novartis AG 
6. Tibotec Pharmaceuticals Ltd 16. Euro-Celtique S.A. 
7. Cipla Limited 17. Intermune Inc. 
8. Takeda Pharmaceutical Company 18. Ranbaxy Laboratories Limited 
Limited 
9. Panacea Biotec Limited 19. Centre National de Ia Recherche 
Scientifique 
10. Janssen Pharmaceutica N.V. 20. Medivir AB 
22 
Price of Essential Medicines: 
These medicines were picked from the MLEM 20th edition. . According to a WIPO Research 
carried out by Reed F Beall form the University of Ottawa, these medicines are on patent within 
the developing countries. 56 Kindly note that the medicines might not be on patent within Kenya, 
as there exists generic medicines in the market. The aim of this price comparison is to juxtapose 
generic prices and original prices. 
Artemether + lumfrantine Chemist 1 Chemist 2 
Use MALARIA 
Availability Yes Yes 
Dosage 8 tablets for 3 days 
Price (Ksh) - Original 80 (Comiem) 400 
Price (Ksh) - Generic 60 200 
Ome(!razole Chemist 1 Chemist 2 
Use GASTROESOPHAGEAL REFLUX 
Availabilty Yes Yes 
Dosage Relative to the disease 
Price (Ksh) - Original 43 (per tablet) 120(per capsule) 
Price (Ksh) - Generic 16 (per tablet) 5 (per tablet) 
CHEMIST 1 - F AIZ PHARAMCY (Located in Mombasa CBD) 
CHEMIST 2- STRATHMORE MEDICAL CLINIC (Located in Nairobi, at the University) 
56 Patents and the WHO Model List of Essential Medicines (18th Edition): Clarifying the Debate 
on IP and Access, World Intellectual Property Organization. 
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Essential Medicines on Patent within ARIPO: 
ABACA VIR (ABC): (HIV/AIDS) 
This is a drug that is in the Model list for essential medicines (20th edition). It is generally 
recommended for infants and children as an ARV treatment. The basic patent had expired in 
2010, secondary patents related to hemisulfate salt, pediatric composition were filed and granted 
by the ARIPO to GSK. GSK has already started to enforce its patent in many countries. The 
medicines patent pool had announced a licence agreement of ABC covering 118 countries, which 
include the ARIPO region. Since Kenya is part of the ARIPO region, it could therefore affect the 
Kenyan population hence precluding generic producers from manufacturing this drug. 57 
DIDANOSINE: (HIV/AIDS) 
It is a drug that is recommended for HIV/AIDS. The enteric coated capsules are included in 
WHO's Model List of Essential Medicines. Since this product is patent free in India, hence 
generic versions have been launched. As for the ARIPO region affordable importation of 
generic versions from India would be blocked (MSF, 2013) due to patents on the product. In 
June 2011, BMS signed an immunity-from-suit agreement with Mylan enabling the genenc 
company to manufacture and sell ddl in sub-Saharan Africa (MSF, 2013). 58 
RITONA VIR AND LOPINA VIR: 
Kaletra; a combination of two antiretroviral agents ritonavir and lopinavir (included in the 
MLEM), its patent had set to expire in 2014 and 2016 respectively. Abott has filed a number 
secondary patents which bar entry of generic versions in certain markets up until 2028 i.e .. 12 
57 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
27. 
58 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
28. 
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years after the basic compound patent expires and 39 years after the first patent for ritonavir was 
filed (I-MAK, 2012).59 
ANALYSIS ON DATA GATHERED 
Given that the Gross National Income of the Kenyan population is USD 1380 per capita (that 
amounts to approximately Ksh. 12,000 per month), according to the 2016 World Bank statistics. 
It is evident that the average Kenyan has a very limited purchasing power especially with regard 
to healthcare and given that diseases are widespread such as HIV/AIDS and Malaria, a real 
change needs to occur in both the legal and government sector. 
It is quite evident from the findings above that the original medicines are way more costly than 
the generic medicines. Even though these findings are restricted to just two chemists, it does 
indicate, however, that there is a price disparity between the original medicine and the generic. 
Hence emphasising on the point that generic medicines (especially for essential medicines) are 
more economically accessible to the population at large. Therefore Kenyan IP laws need to place 
an emphasis on guaranteeing the access to generic medicines (including essential medicines) . As 
for the issue of evergreening as seen in the case of Abacavir, Ritonavir and Lopinavir, the criteria 
for patentability needs to be stricter in order to preclude secondary patents from being granted. 
This is because secondary patents would restrict access to essential medicines, in this case ARV 
medicines, which are crucial to the public at large due to the deaths that occur as a result ofHIV. 
59 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 




Paul Omondi Ogendi 
December 2017 
The interview conducted was with regard to essential medicines and how patents have affected 
the access of such medicines. 
Mr Paul Omondi has a specialisation in intellectual prope1iy rights with regard to access to 
medicines. His thesis was based on access to essential medicines and the utilization of 
compulsory licensing and parallel importation in Kenya and South Africa. He contends that 
access to essential medicines is a human rights issue that needs addressing. There are two 
' 
schools of thought the debate of access. One school argues that there are other factors that 
affect access to essential medicines and that intellectual property rights do not pose as a serious 
threat to access. Whereas the other group argues, that intellectual property rights do pose to be a 
serious threat especially when one looks at the current condition of the healthcare sector and the 
expensive medicines that are common to find within the pharmaceutical industry. 
Amir Attaran a scholar who has written on the topic argues that the pharmaceutical industry is 
not negatively impacted by intellectual prope1iy rights. Holger Hestermeyer, however, in his 
book on human rights and the WTO: The case of patents and access to medicines provides a 
comprehensive study on the conflict between human rights law and patent law and the need for 
the integration between the two. 
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CHAPTER 5: RESEARCH QUESTIONS 
What factors affect inaccessibility of essential medicines in Kenya? 
For the purposes of this paper access can be defined as affordability and availability of essential 
medicines by the Kenyan populace. 
Article 12 of the International Covenant of Economic Social and Cultural Rights (ICESCR), 
provides for the right for everyone to enjoy the highest attainable standard of physical and 
mental health and it also provides that "the steps to be taken by state parties present to the 
covenant to achieve the full realization of this right shall include necessary for . ... prevention, 
treatment and control of epidemic, endemic, occupational and other diseases" and " the creation 
of conditions which would assure to all medical service and medical attention in the event of 
sickness." 60 
It is important to note that according to General Comment No. 14 of the "Right to the highest 
attainable standard of health", access to health (which includes access to essential medicines) 
was defined using three elements 
1) Physical accessibility: This means that the population should have physical access (i.e. within 
reach) to the health goods and services. 
2) Economic accessibility: This means that the health goods and services should be affordable. 
3) Information accessibility: This is related to the right to seek, receive and impart any data 
regarding health related issues e.g. treatment and pricing. 
Therefore it could be inferred from this definition of access, (in this case access to essential 
medicines) can be categorised to physical, economic and information access. This paper will 
mainly focus on the physical and economic i.e. availability and affordability. 
Given the statistics regarding the health situation in developing countries it is important to point 
out the circumstances that contribute to this unfortunate situation. Access to medicines plays a 
major in the public health sector. Some of these factors include; the high levels of poverty in the 
developing countries, the poor governance on the part of the government, inadequate 
infrastructure and obsolete legal frameworks that need to be reformed. 
60 A1iicle 12, International Covenant of Economic Social and Cultural Rights, 16 December 
1966, 993 UNTS 3. 
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This paper looks at whether intellectual property rights play a role in restricting or blocking the 
access to essential medicines in Kenya, in terms of physical and economic access 
As to the question of whether patents are a barrier to the access of essential medicines, it is 
important to note that patents can eliminate competition on the products that are patented and 
this leads to the high prices of the medicines during the period of the patent. This coupled with 
the increasing need of the essential medicines can defeat the aim of access to essential medicines. 
Hence it is imperative that granting of such intellectual property rights should be restricted. 
Many times pharmaceutical companies apply for multiple patents for a single a pharmaceutical 
compound (e.g. patents over new forms, derivatives, uses, combinations, formulations and even 
dosages) - a practice commonly known as "evergreening", therefore keeping the medicine free 
from competition and enabling high pricing.61 
Patents have also been at friction between private interests and public interests. Pharmaceutical 
companies argue that they need patent protection in order to cater for their research and 
development costs, whereas the public has to face the high costs of medicines as a consequence 
of such patents. It has been argued, however, that the costs involved for research and 
development of new medicines are relatively low.62 
How multilateral trade agreements, bilateral trade agreements and domestic 
laws have affect ed the Intellectual Property Rights for access to essential 
medicines in Kenya. 
This paper focuses on the TRIPS agreement, ARIPO, the Industrial Property Act of Kenya and 
the Pharmaceutical Policy in the East African Community: Burundi, Kenya, Uganda, Rwanda, 
and Tanzania. 
61 Opati, ' Intellectual Propetiy Rights in Kenya', 16 
62 Opati, ' Intellectual Property Rights in Kenya', 22 
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TRIPS 
Compulsory licensing is arguably the most effective flexibility within the TRIPS agreement. It 
allows for the government to permit companies the use, manufacture,sell,or import a product 
under patent provided that certain conditions are met. 63 
The Doha Declaration on Public Health and the TRIPS Agreement (Doha Declaration) which 
provides for the use of compulsory licenses states in the effect, that members have the 'freedom 
to determine the grounds for the granting of compulsory licences.' These grounds could include; 
public health, public interest or national emergency situations (although this list is not 
exhaustive). 
Some of the conditions stipulated under Article 31 of TRIPS agreement include; 
1. That the granting of compulsory licences should be considered on individual merits. 
2. Article 31 (b) provides that the patent owner must be promptly informed, and give an 
express authorization on reasonable commercial terms. This however does not apply to 
situations of 'national emergency or other circumstances of extreme urgency or in cases 
of public non-commercial use'. 
3. Compulsory licences that are granted are of limited scope and duration, taking into 
account the 'purpose for which it was granted'. This means that the purpose and duration 
ofthe compulsory licence must be clearly defined. 
4. Once a compulsory licence has been granted it should be non-exclusive i.e. it should be 
available for everyone to use or exploit. 
5. Compulsory licenses are non- assignable by any other enterprises unless it receives a 
grant from the State or enjoys similar goodwill. 
6. The compulsory licence should take into account the commercial interests of the patent 
owner and hence use it strictly for domestic consumption. In 2003 a decision was 
rendered at the World Trade Organization (WTO) TRIPS Agreement General Council, 
which allows least developed countries (countries with insufficient manufacturing 
capacity) for limited exportation and importation of pharmaceutical products. 
7. Compulsory licence expires once the conditions that led to it have ceased to exist. 
63 Article 7, The Agreement on Trade-Related Aspects of Intellectual Property Rights 
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8. Adequate remuneration must also be given to the patent owner although the need to 
correct anti-competitive practices need to be considered while remunerating the owner. 
9. The granting of the compulsory licence can be challenged in a court of law or 'other 
independent review by a distinct higher authority'. This includes challenges on the 
remuneration. The Dispute Settlement Body of the WTO, however, has not been able to 
set a precedent for concluding whether they are legal under the TRIPS Agreement. A case 
to be noted is when the USA had disputed its legality under the TRIPS agreement when 
South Africa had authorized the Minister of Health to be able to issue compulsory 
licenses for pharmaceuticals.64Another case in point is when the USA had disputed the 
granting of compulsory licenses by India of a cancer drug called Nexavar. Last year the 
case was finally settled by the Patent controller of India, by granting the country's first 
compulsory licence. 65 The judgement provided that the patent owner, Bayer, had not met 
the reasonable requirement of the public i.e. it did not satisfy the needs of the Indian 
populace and the drug was also expensive for the public. A spokesperson from Bayer 
responded to this by noting that their intellectual property rights had been infringed in 
India. 
It can be concluded that the flexibility of compulsory licences within the TRIPS agreement is 
very complex and it is unclear whether these compulsory licences are used adequately within 
countries that need it most. As sited from the case above it seems that there is a struggle between 
certain stakeholders whether or not to grant these compulsory licenses. 
Industrial Property Act, Kenya 
Section 58 of the Industrial Property Act (IPA) provides for the limitations of rights. It provides 
for as follows " ... The rights under the patent shall be limited by the provisions on compulsory 
licences for reasons of public interest or based on interdependence of patents and by the 
provisions on State exploitation of patented inventions .... ". 66 This provision sets the foundation 
640mondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
parallel importation in Kenya and South Africa' Unpublished LLM Thesis, University of 
Nairobi, 2013, 44. 
65http://www.thehindubusinessline.com/companies/Indias-first-compulsory-licence-granted-to-
Natco-for-Bayers-cancer-drug/article20408026.ece at 04-02-2018 
66 Section 58, Industrial Property Act, 2001 
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for the flexibility of compulsory licensing. It can be inferred that patent laws can be infringed in 
cases of 'public interest', which could include the access to essential medicines. 
Sections 72 to 78 generally provide for the laws governing compulsory licensing. The grounds, 
provided in sections 72 and 73, for granting a compulsory license include "supply on reasonable 
terms" and "interdependence of patents". The supply on reasonable terms entails that if four 
years after the filing of a patent or three years after a patent has been granted there are no 
supplies in the market on reasonable terms without any justification another person may apply 
for a compulsory license in Kenya.67 Other preconditions for obtaining a compulsory license are 
set out in Section 74 e.g. the person requesting the license must prove that he was 'unable to 
obtain the license on reasonable commercial terms', although this does not for national 
emergencies. 
In Kenya the compulsory licensing process is handled by the Industrial Property Tribunal. It is 
argued that the processes involved within the courts in developing countries are often 
burdensome and costly. Therefore it is unlikely that the local pharmaceutical companies would 
try and obtain compulsory licences for essential medicines because they would be unwilling to 
cater for the costs and resources accompanied. 68 
In 2007, Kenya's parliament rejected a proposal to revoke the government's power to issue 
compulsory licences. This has not been the first time that such a proposal was made. If the 
government had lost its powers to issue compulsory licences, it would not be allowed to permit 
the use and manufacture of generic medicines, without the permission from pharmaceutical 
companies. 69 
67 Omondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
parallel impmtation in Kenya and South Africa' Unpublished LLM Thesis, University of 
Nairobi, 2013, 45 
68 Omondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
parallel importation in Kenya and South Africa' Unpublished LLM Thesis, University of 
Nairobi, 2013, 45 
69https://www.ip-watch.org/2007/09/14/kenyan-parliament-rejects-bid-to-remove-governements-
compulsory-licensing-option/ at 25/0112018 
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One of the mam legal challenges of compulsory licenses is that the TRIPS agreement is 
ambiguous with regard to the 'reasonable' paid to the patent holder; this is very confusing since 
there are not set criteria for determining the compensation. This can then result to legal battles 
whether the compensation was adequate or in Kenya's case, equitable. Therefore, making it 
undesirable for local manufacturers from obtaining them.70 
ARIPO 
Kenya is one of the developing countries within the ARIPO Region. Despite this fact, the Harare 
Protocol does not provide for exemptions for the Least Developed Countries from the processing 
of patent filings for pharmaceuticals (LDCs are given a transition period (but the Harare Protocol 
does not provide for this). This brings about a barrier to access of essential medicines because 
they provide the opportunity for essential medicines to be patented. Uganda and Rwanda have 
incorporated in their national laws the pharmaceutical product transition period. This is 
imperative for the access to essential medicine to the public because such legislation gives 
essential medicines an exemption from patent protection. 71 
Another major issue with the Harare Protocol is the patentability criteria. It is argued that 
ARIPO's patentability criterion is too lax hence providing a broad range of pharmaceutical 
products to be patented including essential medicines. This includes secondary patents which 
extend the patent protection to forms of new chemical entity such as new formulations, 
combinations, dosages and uses. These secondary patents have been strategically used to 
"evergreen" patents by pharmaceutical companies hence extending their patent monopoly and 
bringing an undue delay for the entry of generic industry. This, consequently, adversely affects 
the affordability of essential medicines. It would therefore be important that ARIPO adopt a 
rigorous patentability criterion that would preclude the situation of 'evergreening' or secondary 
patents. 
70 Omondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
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Specific rules should be adopted with regard to the examination and grant of pharmaceutical 
patents. This will then prevent a situation where essential medicines are subject to prolonged 
patent protections. 72 
Pharmaceutical Policy in the Eas t Afri can Community: Burundi, Kenya, Uganda, Rwanda, 
Tanzania 
The East African Community (EAC) is mainly governed by the East African Community Treaty. 
This policy was intended to improve access to medicines through regulatory harmonization in 
the East African Community. This policy focuses on action in three areas, namely, access, 
quality, and rational use.73 
Article 118 of the Treaty provides for the governing of health, joint action towards the control 
and prevention of communicable and no-communicable diseases, harmonization of health 
policies and regulations and promoting the exchange of information in order to achieve quality 
health within the Community and cooperation in development of pharmaceutical products. 
Within the East African Community, all countries have their National Medicines Policy (NMP), 
these policies were formed using the WHO recommendations, some of these recommended 
components include; 74 
Supply: local production, procurement mechanisms, distribution and storage, disposal of 
unwanted or expired medicines; 
Rational use: STGs, Medicines Information, rational medicine use for training, education, 
promotion; 
Affordability: taxes or tariffs on essential medicines, pncmg, use of genencs, TRIPs 
mechanisms; 
72 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
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Legislative and regulatory framework: Drug Regulatory Authorities, good governance for 
medicines, legislation and regulation, medicines registration and licensing, quality assurance 
(inspection and enforcement), regulation of prescription and distribution. 
It is important to note that these policies are intended to promote access to essential medicines 
within the East African region by urging member states to use the TRIPS flexibilities 
exhaustively. 75 
All the member states have provided for implementation for their policies through legislation, 
but the problem is that the legislation is often out-dated and therefore not relevant in its time and 
context.76 
75 Mashingia J,' Pharmaceutical Policy m the East African Community: Burundi, Kenya, 
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CONCLUSION 
What is the way forward with regard to access to essential medicines in 
relation to Intellectual Pr operty rights? 
The Kenyan Constitution provides for Economic and social rights under Article 43 , which 
provides for the highest attainable standards of health care services. This right, however, has not 
been realized because of the major diseases such as HIV I AIDS pandemic widespread within the 
country and the exorbitant prices or the lack of availability of the essential medicines within the 
country. It is true that there are many factors that have contributed to this situation, such as lack 
of infrastructure, poor governance, corruption and high poverty levels . Intellectual property 
rights, however, are also a contributing factor which has impacted the accessibility of essential 
medicines. An example is the Patricia Asero case which confirmed the right to health enshrined 
in the Constitution and it also, by extension, included the right to access essential medicines. 
This was done by rendering Anti counterfeit Act unconstitutional as it sought to prohibit the 
access to affordable generic medicines. Therefore, there needs to be a more robust and practical 
legal framework put in place that would aid in the accessibility of essential medicines. 
RECOMMENDATIONS 
Kenya needs to establish a transparency mechanism that enables the information relating to 
patented medicines to be freely available to the public, e.g. making it available in their websites 
with sufficient information that relates to the patent. Kenya Industrial Propetiy Institute, 
therefore, needs to make public its databases, giving adequate patent information. 77 
Kenya's patentability criteria should be rigorous enough to prevent situations of evergreening or 
secondary patents that prolong the patent period of medicines as noted below: 
"The EAC states shall provide for and apply a strict novelty requirement through considering a 
wide concept of prior art, including everything disclosed to the public whether by use, in written 
or oral form, including patent applications, information implied in any publication or derivable 
from a combination of publications, which are published anywhere in the world and which can 
be accessed by the general public; (b) shall provide that the non-obviousness of an invention 
77 Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines' South Centre Research Paper 56, November 2014, 
48. 
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shall be determined on the basis of a person who is highly skilled in the art; (c) shall strictly 
apply the industrial application requirement and limit the patentability of research tools to only 
those for which a specific use was identified."78 
Kenya should include in its National Medicine policy the guarantee of generic medicines, since 
generic medicines are relatively cheaper than branded medicines. This is clearly demonstrated in 
the findings above. 79 
As for compulsory licenses, Kenya could change the law with regard to granting a compulsory 
licence only for the domestic market (Section 75 2(b)). This is in order to allow for limited 
imports and exports in which are provided for Paragraph 6 Decision of the TRIPS General 
Council of30 August 2003 .80 
78Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
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80 Omondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
parallel importation in Kenya and South Africa' Unpublished LLM Thesis, University of 




Opati L, Intellectual Property Rights in Kenya, Konrad Adenauer Stifung, Nairobi, 2009. 
CASES: 
Patricia Asero Ochieng and 2 others v Attorney General and Another [2009] 
LEGISLATION: 
Constitution of Kenya 
Industrial Property Act, 2001 
INTERNATIONAL INSTRUMENTS 
The Agreement on Trade-Related Aspects of Intellectual Prope1iy Rights, 1 January 1995, 1869 
UNTS 299. 
The African Regional Intellectual Property Organization (ARIPO) Protocol (Harare Protocol) 
Pharmaceutical Policy in the East African Community: Burundi, Kenya, Uganda, Rwanda, 
Tanzania 
International Covenant of Economic Social and Cultural Rights, 16 December 1966, 993 UNTS 
3. 
Universal Declaration of Human Rights 
Convention establishing the World Intellectual Property Organisation 
THESIS: 
Omondi P, 'Access to essential medicines and the utilization of compulsory licensing and 
parallel importation m Kenya and South Africa' Unpublished LLM Thesis, University of 
Nairobi, 2013 
Ndlovu L, ' Access to medicines under the world trade organisation TRIPS agreement: A 




Sangeeta S, 'The African Regional Intellectual Property Organization (ARIPO) Protocol on 
Patents: Implications for access to medicines ' South Centre Research Paper 56, November 2014 
JOURNALS: 
Hettinger E, ' Justifying Intellectual Property' Volume 18 Philosophy and Public Affairs (1989) 
WEBSITES: 
http://www.iep.utm.edu 
https://www.cugh.org 
https://www.ncbi.nlm.nih.gov 
https://www.ip-watch.org 
http://www.ohchr.org 
http://kelinkenya.org 
38 
